Text Size

Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00110019
First received: May 3, 2005
Last updated: December 20, 2012
Last verified: December 2012
History of Changes
Results First Received: August 28, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Mucosal Melanoma
Recurrent Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma
Interventions: Drug: sorafenib tosylate
Other: placebo
Drug: carboplatin
Drug: paclitaxel
Other: pharmacological study
Other: laboratory biomarker analysis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study was activated on June 23, 2005, and terminated on April 22, 2008 with the final accrual of 823 patients. Most of patients were accrued through Eastern Cooperative Oncology Group (ECOG), Cancer and Leukemia Group B (CALGB), and Southwest Oncology Group (SWOG). Other Clinical Trials Cooperative Groups also participated.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm I (Carboplatin+Paclitaxel+Sorafenib) Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral sorafenib twice daily on days 2-19.
Arm II (Carboplatin+Paclitaxel) Patients receive paclitaxel and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 2-19.

Participant Flow:   Overall Study
    Arm I (Carboplatin+Paclitaxel+Sorafenib)     Arm II (Carboplatin+Paclitaxel)  
STARTED     410     413  
Eligible     395     398  
Treated     393     397  
COMPLETED     4     0  
NOT COMPLETED     406     413  
Lack of Efficacy                 253                 285  
Adverse Event                 61                 40  
Death                 13                 15  
Withdrawal by Subject                 21                 9  
alternative therapy                 5                 1  
complicating disease                 1                 1  
symptom deterioration                 13                 16  
Not start protocol therapy                 17                 16  
other reasons                 22                 30  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Arm I (Carboplatin+Paclitaxel+Sorafenib) Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive oral sorafenib twice daily on days 2-19.
Arm II (Carboplatin+Paclitaxel) Patients receive paclitaxel and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 2-19.
Total Total of all reporting groups

Baseline Measures
    Arm I (Carboplatin+Paclitaxel+Sorafenib)     Arm II (Carboplatin+Paclitaxel)     Total  
Number of Participants  
[units: participants]
 		  410     413     823  
Age  
[units: years]
Median ( Full Range ) 		  60  
  ( 19 to 86 )   		  58  
  ( 18 to 84 )   		  59  
  ( 18 to 86 )  
Gender  
[units: participants]
 		     
Female     140     162     302  
Male     270     251     521  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: Survival was assesed every 3 months if patient is < 2 years from study entry. Every 6 months is patient is 2-5 years from study entry. ]
  Show Outcome Measure 1

2.  Secondary:   Progression-free Survival   [ Time Frame: Tumor response was assessed after every 2 cycles during cycle 1 through 10, and every 3 cycles after cycle 10. Survival was assesed every 3 months if patient is < 2 years from study entry, and every 6 months if 2-5 years from study entry. ]
  Show Outcome Measure 2

3.  Secondary:   Objective Response (Complete and Partial Response) Rate   [ Time Frame: Tumor response was assessed after every 2 cycles during cycle 1 through 10. After cycle 10, tumor response was assessed after every 3 cycles. ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Study Statistician
Organization: ECOG Statistical Office
phone: 617-632-3012


No publications provided by National Cancer Institute (NCI)

Publications automatically indexed to this study:


Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00110019     History of Changes
Other Study ID Numbers: NCI-2012-02978, E2603, U10CA021115, CDR0000423315
Study First Received: May 3, 2005
Results First Received: August 28, 2012
Last Updated: December 20, 2012
Health Authority: United States: Food and Drug Administration